Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers

Raloxifene hydrochloride (RLX) shows poor bioavailability (<2%), high inter-patient variability and extensive gut metabolism (>90%). The objective of this study was to develop nanostructured lipid carriers (NLCs) for RLX to enhance its bioavailability. The NLC formulations were produced with g...

Descripción completa

Detalles Bibliográficos
Autores principales: Murthy, Aditya, Rao Ravi, Punna, Kathuria, Himanshu, Malekar, Shrinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353254/
https://www.ncbi.nlm.nih.gov/pubmed/32486508
http://dx.doi.org/10.3390/nano10061085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353254/
https://www.ncbi.nlm.nih.gov/pubmed/32486508
http://dx.doi.org/10.3390/nano10061085

Ejemplares similares